樂天醫藥 - Rakuten Medical

Rakuten Medical Logo

Pipeline

產品線

樂天醫藥產品線

樂天醫藥將繼續推進其研究產品線，以期儘快提供創新癌症療法。目前，樂天醫藥正在進行一項使用ASP-1929在復發性頭頸部鱗狀細胞癌患者的全球3期多中心臨床研究。此外，研究ASP-1929與抗-PD1組合在多種腫瘤類型中的早期臨床研究也已計畫或正在進行中（請參考www.ClinicalTrials.gov）。另外，樂天醫藥正在進行RM-1995等研究性分子的其他早期研究。關於我們完整開發產品線的更多詳情請參考：

免責聲明：ASP-1929 光免疫療法在日本以外地區仍處於研究階段。 ASP-1929於2020年9月獲得日本厚生勞動省的上市許可，並於2021年1月正式上市。
a 此為與島津製作所和國立衛生研究院國立癌症研究所合作的研究。機會窗臨床試驗發生在診斷出癌症之後到開始標準治療之間，患者在這段時間內接受非標準藥物或感興趣的治療ⅰ ⅱ
ⅰAroldi F, Lord SR. Window of opportunity clinical trial designs to study cancer metabolism. Br J Cancer. 2020;122(1):45-51. doi:10.1038/s41416-019-0621-4
ⅱ Schmitz S, Duhoux F, Machiels JP. Window of opportunity studies: Do they fulfil our expectations? Cancer Treat Rev. 2016 Feb;43:50-7. doi: 10.1016/j.ctrv.2015.12.005. Epub 2015 Dec 31. PMID: 26827692.

參考來源: 公司資料; ClinicalTrials.gov, JAPIC

(1)研究者發起的試驗
(2) 計畫於2022年開始的試驗
截至 2022 年 4 月 8 日

該產品線圖形代表了一系列RMI的候選產品，且被設計為證明我們在克服癌症的旅程中對患者的承諾。隨著產品開發過程的進展，RMI的產品線將隨著時間推移而變化，包括在適用情況下從臨床階段進入許可階段、進入合作關係、獲得許可及停止許可、或臨床試驗證實療效或安全性或轉化為商業產品時失敗，這些全部取決於藥品和器材開發過程的性質。本說明包含設計重要風險和不確定性的前瞻性聲明，且實際結果可能會有重大差異。除非另行說明，否則RMI提供的此資訊截止至2021年5月10日，RMI明確表示對因新資訊、未來時間或其他原因而對本表中已提供資訊或前瞻性聲明進行的更新，不會承擔任何責任。

People
×
Innovation
×
Action
×
A Note from Our Chairman

In 2012, my father was diagnosed with pancreatic cancer. I was ready to do anything for him to be cured. With that sole purpose, I read many scientific papers from all over the world, and I met and talked with numerous experts in the field. How could I cure my father’s cancer? I searched every single possibility available.

That is when I found out about photoimmunotherapy that was only at an early stage of research. Although I had many doubts about this completely new approach, desperate for a miracle, I immediately went to meet the researcher.

Everyone was still doubtful at that stage. But the more I heard about this research, the more it made sense. 

I instinctively thought, “This is it.” It was the same feeling I got as when I grasped that the internet would change the world forever. Somehow, wishing to save my father, I immediately made up my mind to support the research personally to speed it up.

Unfortunately, we didn’t make it in time to save my father. But I decided to continue my support. My father who was as an economist always said, “One important mission of corporations is to contribute to humanity.”

Left behind, I resolved to provide this latest treatment to as many people as possible. It will surely be a path fraught with difficulties. But right at this moment there are many who are suffering from cancer, many who wish to save the lives of their loved ones, and I know exactly how they feel.

To provide this treatment as soon as possible, to bring this treatment to as many people as possible, I will not fail to support this research from now on.

Chairman, Rakuten Medical, Inc.

Hiroshi Mikitani

×